Clopidogrel for Reduction of Atherosclerotic Events
Clopidogrel bisulfate (Plavix - Bristol-Myers Squibb/Sanofi), a new thienopyridine antiplatelet agent similar to ticlopidine (Ticlid - Medical Letter, 34:65, 1992), has been approved by the US Food and Drug Administration (FDA) for secondary prevention of myocardial infarction, stroke and other vascular events....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Clopidogrel for Reduction of Atherosclerotic Events
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1028
Article Code: 1028a
Date: June 5, 1998
Volume: 40
Pages: 59-60
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1028
Article Code: 1028a
Date: June 5, 1998
Volume: 40
Pages: 59-60
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)